Fig. 3
From: A subset of diffuse-type gastric cancer is susceptible to mTOR inhibitors and checkpoint inhibitors
Identification of temsirolimus as a potent growth inhibitor for diffuse-type GC-initiating cells. a Effect of temsirolimus, bortezomib, and YM155 on the growth of HGC-3 and -20 cells in vivo, compared with controls (DMSO). b Effect of temsirolimus, everolimus, and PP242 on the growth of HGC-3 and -20 cells in primary culture. c Effect of temsirolimus, everolimus and PP242 on the growth of HGC-3 and -20 cells in vivo, compared with controls (DMSO). Mean ± SD of three (a, c) and five (b) independent experiments. * P < 0.05, ** P < 0.01 (Student’s t-test compared with controls (Cont))